Semaglutide, sold as Wegovy and Ozempic, may reduce opioid overdoses in people with opioid-use disorder and type 2 diabetes.

Demand forweight-loss drugs has grown at an astonishing rate in recent years, driving share prices of healthcare giants such ...

Per Dr. Wheeler, some signs that metformin may not be working are persistently high blood glucose levels and no improvement ...

Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic ...

U.S. representative from Austin asks Health and Human Services secretary to push for generic licensing of semaglutide ...

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

Ozempic has recently taken social media by storm, gaining attention for its ability to induce rapid weight loss along with ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established drugmakers and an emerging market of compounded versions as telehealth ...

The future of oral weight loss medication looks bright. Drug manufacturer Novo Nordisk announced a new experimental ...